Clinical Trials in the UK / NCT05163041
Active, not recruiting
Phase 1/2
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
NCT05163041 · tracked via the Priya Life Science UK tracker
Condition(s) studied
Advanced Solid Tumor
Investigational drug(s) / intervention(s)
BT7480Nivolumab →
BT7480: Participants will receive a 60 minute IV infusion of BT7480 once weekly (i.e., on Days 1,8,15 and 22) during a 28-day cycle
Nivolumab: Nivolumab will be given as a 240mg dose every 2 weeks administered as per local labelling as a 30 minute IV infusion
Study summary
This clinical study is evaluating a drug called BT7480 alone and in combination with nivolumab in participants with advanced solid tumors associated with Nectin-4 expression.
The main goals of the study are to:
* Find the recommended dose of BT7480 that can be given safely to participants alone and in combination with nivolumab
* Learn about the side effects and effectiveness of BT7480 alone and in combination with nivolumab
* Learn about the effect BT7480 has on the body and how BT7480 is cleared by the body
* Learn about the side effects and effectiveness of BT7480 in patients with reduced kidney function
Eligibility
Inclusion Criteria:
* Must have locally advanced or metastatic disease that is refractory to standard therapy, or for which no standard therapy is judged to be appropriate or provide clinical benefit, as judged by the Investigator
* Must have a histologically or cytologically confirmed malignant solid tumor associated with Nectin-4 expression, including, but not limited to, urothelial (transitional cell) carcinoma; head and neck squamous cell carcinoma; non-small cell lung cancer; and ovarian, breast, gastric, or esophageal carcinoma
* Must have ECOG performance status score 0 or 1 and acceptable organ and hematological function
* Must have metastatic or locally advanced disease and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
* Life expectancy ≥12 weeks
* Must submit fresh or archival tumor tissue
* Must provide written informed consent, according to local guidelines, signed and dated by the patient or by a legal guardian prior to the performance of any study-specific procedures, sampling, or analysis
Exclusion Criteria:
* Prior therapy with a cytotoxic, small molecule, or other systemic chemotherapy within 14 days of the first dose of study drug
* Prior immunotherapy, including monoclonal antibodies, within 28 days or 5 half-lives of the first dose of study drug, whichever is shorter
* Prior treatment with CD137 targeted therapy
* Mean resting QTc (eg, QTcF) greater than 470 msec on triplicate electrocardiograms (ECGs) obtained at screening
* Uncontrolled symptomatic brain metastases
* Uncontrolled diabetes with glycosylated hemoglobin greater than or equal to 8%
* Uncontrolled hypertension at screening or prior to initiation of study drug
* History of autoimmune disease except well-controlled diabetes mellitus, alopecia, well controlled thyroid disease or vitiligo
Primary outcome measure(s)
- Number of patients with treatment emergent adverse events in dose escalation phase — From Cycle 1 Day 1 (each cycle is 28 days) until 30 (+/-5) days after the last dose of study drug
Incidence and severity of treatment emergent adverse events to assess safety and tolerability following treatment with BT7480 alone and in patients with renal insufficiency using NCI CTCAE v5.0 criteria - Number of patients with treatment emergent adverse events in dose escalation phase — From Cycle 1 Day 1 (each cycle is 28 days) until 125 (+/-5) days after the last dose of study drug
Incidence and severity of treatment emergent adverse events to assess safety and tolerability following treatment with BT7480 and in combination with nivolumab using NCI CTCAE v5.0 criteria - Confirmed response rate as measured by overall response rate (ORR) to demonstrate clinical activity following treatment with BT7480 in dose expansion phase — From Cycle 1 Day 1 (each cycle is 28 days) through study completion, an average of 6 months
Overall response rate (ORR) following treatment with BT7480 alone and in combination with nivolumab according to RECIST 1.1 criteria nivolumab according to RECIST 1.1 criteria - Confirmed response rate as measured by clinical benefit rate (CBR) to demonstrate clinical activity following treatment with BT7480 in dose expansion phase — From Cycle 1 Day 1 (each cycle is 28 days) through study completion, an average of 6 months
Clinical benefit rate (CBR) following treatment with BT7480 alone and in combination with nivolumab according to RECIST 1.1 criteria nivolumab according to RECIST 1.1 criteria
Trial sites (9)
| Facility | City | Region | Status |
|---|---|---|---|
| State University of Iowa | Iowa City | Iowa | |
| Columbia University Irving Medical Center | New York | New York | |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | |
| MD Anderson Cancer Center | Houston | Texas | |
| START Center for Cancer Care | San Antonio | Texas | |
| Virginia Cancer Specialists | Fairfax | Virginia | |
| The Royal Marsden NHS Foundation Trust | Sutton | Surrey | |
| The Beatson West of Scotland Cancer Centre | Glasgow | United Kingdom |
On this site
📄 Opdivo (nivolumab) drug profile →More BicycleTx Limited trials in the UK
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Active, not recruiting
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
Active, not recruiting
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
Active, not recruiting
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
Active, not recruiting
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05163041 on ClinicalTrials.gov ↗ ← All trials in the UK